GlassScriptPhysician profile
Suzanne H Blasko
NPI 1548215890
$669.31
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $74.40 · 2021: $95.54 · 2022: $86.52.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $230.67 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $87.47 | 2019-2022 | |
| Novo Nordisk INC | $54.89 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.40 | 2019-2020 | |
| Pfizer INC. | $39.60 | 2019 | |
| Lilly USA, LLC | $37.06 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.78 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.53 | 2019-2020 | |
| Amgen INC. | $22.00 | 2019 | |
| Abbvie INC. | $17.48 | 2021 | |
| Astellas Pharma US INC | $15.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Blasko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.